IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v39y2021i11d10.1007_s40273-021-01068-9.html
   My bibliography  Save this article

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial

Author

Listed:
  • Michael Dolph

    (Purple Squirrel Economics Montreal)

  • Gabriel Tremblay

    (Purple Squirrel Economics Montreal)

  • Hoyee Leong

    (Karyopharm Therapeutics)

Abstract

Background and Objective Nearly all patients with multiple myeloma undergo multiple rounds of therapy. The phase III BOSTON trial of once-weekly selinexor and once-weekly bortezomib with dexamethasone (XVd) vs twice-weekly bortezomib and dexamethasone (Vd) is the basis for this cost-effectiveness analysis in previously treated multiple myeloma from a US commercial payer perspective over a lifetime horizon. Methods A partitioned survival model enabled use of direct overall survival and progression-free survival curves from BOSTON to generate four health states for XVd and Vd: progression-free survival on treatment, progression-free survival off treatment, post-progression, and mortality. Using a 1-week cycle length, benefits and costs were discounted at 3.0% annually. Additional comparators were included in an exploratory analysis that compared XVd against seven additional regimens (six triplets, one doublet). Results After considering costs, utility, progression, and survival, the base-case incremental cost-effectiveness ratio of XVd vs Vd was $475,430/quality-adjusted life-year (QALY). The 50% cost-effectiveness probability midpoint was near $470,000/QALY, based on a probabilistic sensitivity analysis. The robustness of the analysis was supported by additional scenario assessment and deterministic and probabilistic sensitivity analyses, which generally demonstrated little variance, with greatest sensitivity to variations in discount rates and utility values. In an exploratory analysis against external comparators, XVd showed a higher QALY gain with a lower cost (i.e., dominance) compared with lenalidomide/dexamethasone (Rd), pomalidomide/bortezomib/dexamethasone (PVd), and carfilzomib/pomalidomide/dexamethasone (KPd). Conclusions Addition of XVd to the previously treated multiple myeloma treatment landscape provides a novel oral treatment option, which, when compared to Vd in the base-case analysis resulted in an incremental cost-effectiveness ratio of $475,430/QALY. Exploratory analyses comparing against external comparators suggest that XVd was dominant vs Rd, PVd, and KPd.

Suggested Citation

  • Michael Dolph & Gabriel Tremblay & Hoyee Leong, 2021. "Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial," PharmacoEconomics, Springer, vol. 39(11), pages 1309-1325, November.
    • Handle: RePEc:spr:pharme:v:39:y:2021:i:11:d:10.1007_s40273-021-01068-9
    DOI: 10.1007/s40273-021-01068-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-021-01068-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-021-01068-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Paul T E Cusack, 2020. "On Pain," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 31(3), pages 24253-24254, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sana Sadiq & Khadija Anasse & Najib Slimani, 2022. "The impact of mobile phones on high school students: connecting the research dots," Technium Social Sciences Journal, Technium Science, vol. 30(1), pages 252-270, April.
    2. Jitka Vseteckova, 2020. "Psychological Therapy for ICT Literate Older Adults in the Time of COVID-19 - Perceptions on the Acceptability of Online Versus Face to Face Versions of a Mindfulness for Later Life Group," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 31(1), pages 23912-23916, October.
    3. Khalid Ahmed Al-Ansari & Ahmet Faruk Aysan, 2021. "More than ten years of Blockchain creation: How did we use the technology and which direction is the research heading? [Plus de dix ans de création Blockchain : Comment avons-nous utilisé la techno," Working Papers hal-03343048, HAL.
    4. Ling, Gabriel Hoh Teck & Suhud, Nur Amiera binti Md & Leng, Pau Chung & Yeo, Lee Bak & Cheng, Chin Tiong & Ahmad, Mohd Hamdan Haji & Matusin, AK Mohd Rafiq AK, 2021. "Factors Influencing Asia-Pacific Countries’ Success Level in Curbing COVID-19: A Review Using a Social–Ecological System (SES) Framework," SocArXiv b9f2w, Center for Open Science.
    5. Rafał Krupiński, 2020. "Virtual Reality System and Scientific Visualisation for Smart Designing and Evaluating of Lighting," Energies, MDPI, vol. 13(20), pages 1-17, October.
    6. Óscar Chiva-Bartoll & Honorato Morente-Oria & Francisco Tomás González-Fernández & Pedro Jesús Ruiz-Montero, 2020. "Anxiety and Bodily Pain in Older Women Participants in a Physical Education Program. A Multiple Moderated Mediation Analysis," Sustainability, MDPI, vol. 12(10), pages 1-12, May.
    7. Gigi Foster, 2020. "The behavioural economics of government responses to COVID-19," Journal of Behavioral Economics for Policy, Society for the Advancement of Behavioral Economics (SABE), vol. 4(S3), pages 11-43, December.
    8. Tonata Dengeingei & Laura Uusiku & Olivia N Tuhadeleni & Alice Lifalaza, 2020. "Assessing Knowledge and Practice Regarding the Management of Dysmenorrhea Among Students at University of Namibia Rundu Campus," Global Journal of Health Science, Canadian Center of Science and Education, vol. 12(9), pages 105-105, August.
    9. Craig C Kage & Mohsen Akbari-Shandiz & Mary H Foltz & Rebekah L Lawrence & Taycia L Brandon & Nathaniel E Helwig & Arin M Ellingson, 2020. "Validation of an automated shape-matching algorithm for biplane radiographic spine osteokinematics and radiostereometric analysis error quantification," PLOS ONE, Public Library of Science, vol. 15(2), pages 1-15, February.
    10. Felbermayr, Gabriel & Morgan, T. Clifton & Syropoulos, Constantinos & Yotov, Yoto V., 2021. "Understanding economic sanctions: Interdisciplinary perspectives on theory and evidence," European Economic Review, Elsevier, vol. 135(C).
    11. Zack Cooper & Joseph J. Doyle Jr. & John A. Graves & Jonathan Gruber, 2022. "Do Higher-Priced Hospitals Deliver Higher-Quality Care?," NBER Working Papers 29809, National Bureau of Economic Research, Inc.
    12. William Encinosa & Didem Bernard & Thomas M. Selden, 2022. "Opioid and non-opioid analgesic prescribing before and after the CDC’s 2016 opioid guideline," International Journal of Health Economics and Management, Springer, vol. 22(1), pages 1-52, March.
    13. David G. Blanchflower & Alex Bryson, 2022. "Union Membership Peaks in Midlife," British Journal of Industrial Relations, London School of Economics, vol. 60(1), pages 124-151, March.
    14. Jiaxin Li & Zijun Zhou & Jianyu Dong & Ying Fu & Yuan Li & Ze Luan & Xin Peng, 2021. "Predicting breast cancer 5-year survival using machine learning: A systematic review," PLOS ONE, Public Library of Science, vol. 16(4), pages 1-23, April.
    15. Helene Berntzen & Ida Torunn Bjørk & Ann‐Marie Storsveen & Hilde Wøien, 2020. "“Please mind the gap”: A secondary analysis of discomfort and comfort in intensive care," Journal of Clinical Nursing, John Wiley & Sons, vol. 29(13-14), pages 2441-2454, July.
    16. Axel Hallgren & Anders Hansson, 2021. "Conflicting Narratives of Deep Sea Mining," Sustainability, MDPI, vol. 13(9), pages 1-20, May.
    17. Esmail Shariati & Ali Dadgari & Seyedeh Solmaz Talebi & Gholam Reza Mahmoodi Shan & Hossein Ebrahimi, 2021. "The Effect of the Web-Based Communication between a Nurse and a Family Member on the Perceived Stress of the Family Member of Patients with Suspected or Confirmed COVID-19: A Parallel Randomized Clini," Clinical Nursing Research, , vol. 30(7), pages 1098-1106, September.
    18. Kobayashi, Yoshiharu & Heinrich, Tobias & Bryant, Kristin A., 2021. "Public support for development aid during the COVID-19 pandemic," World Development, Elsevier, vol. 138(C).
    19. Ng Yi Ming & Peter Voo Su Kiong & Ismail Maakip, 2020. "Predictors of Musculoskeletal Disorders Among Teachers: An Exploratory Investigation in Malaysia," Asian Social Science, Canadian Center of Science and Education, vol. 16(7), pages 1-67, July.
    20. Dong Qiu & Zha Zhengang, 2021. "Advance in Etiology and Rehabilitation Treatment of Patellofemoral Pain (Review)," International Journal of Sciences, Office ijSciences, vol. 10(05), pages 35-40, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:11:d:10.1007_s40273-021-01068-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.